| Outcome Measures: |
Primary: Part A: Assessment of glucose homeostasis in fasted condition and after an oral glucose load, following multiple doses of ipragliflozin in healthy subjects and subjects with T2DM, 4 days|Part A: Assessment of peripheral glucose utilization after an oral glucose load, following multiple doses of ipragliflozin, 4 days|Part A: Assessment of splanchnic uptake after an oral glucose load, following multiple doses of ipragliflozin, 4 days|Part A: Assessment of mean glucose levels in fasted condition and after an oral glucose load, following multiple doses of ipragliflozin, 4 days|Part B: Assessment of the relationship between the exposure to ipragliflozin in plasma, urinary glucose excretion and plasma glucose levels in subjects with T2DM, 6 days (PK), 12 days (urine) and 8 days (PD) | Secondary: Part A: Assessment of steady state urinary sodium excretion and urinary glucose excretion following multiple doses of ipragliflozin, 4 days (sodium) and 14 days (glucose) days|Part A: Assessment of energy production and utilization of energy sources following multiple doses of ipragliflozin, 4 days|Part A: Safety and tolerability following multiple doses of ipragliflozin assessed by recording adverse events, laboratory assessments, vital signs, electrocardiograms (ECGs) and signs and symptoms of hypoglycemia, Up to 21 days|Part B: Safety and tolerability following multiple doses of ipragliflozin assessed by recording adverse events, laboratory assessments, vital signs, electrocardiograms (ECGs) and signs and symptoms of hypoglycemia, Up to 21 days
|
